Data completeness
2/8 — Basic
LAMIVUDINE AND STAVUDINE (lamivudine; stavudine) by Hetero is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 8h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMIVUDINE AND STAVUDINE is an oral fixed-dose combination antiretroviral tablet for HIV-1 infection in adults and pediatric patients weighing at least 6 kg. It combines two nucleoside reverse transcriptase inhibitors (NRTIs) to suppress viral replication. The product is sponsored by Hetero and remains in pre-launch stage.
PRE_LAUNCH
Pre-launch status indicates imminent commercial activation; expect significant hiring across medical affairs, regulatory, and field-based roles in the coming months.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE AND STAVUDINE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.